Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Hot Topics of the Day|PHGKB
Search PHGKB:

10/18/2019

Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Sign up MyPHGKB to receive the daily hot topic email alert.

Search Archive:
Archived Hot Topics of the Day By Date

Cost-effectiveness of risk-stratified colorectal cancer screening based on polygenic risk – current status and future potential
SK Naber et al, JNCI SPectrum, October 17, 2019

This cost-effectiveness analysis shows that currently, colorectal cancer screening based on polygenic risk is unlikely to be cost effective compared to uniform screening. This is expected to change with a?>?0.05 increase in AUC value, a?>?30% reduction in polygenic testing costs, or a?>?5% increase in adherence with screening.

Making the Case for Early Statins in Familial Hypercholesterolemia
P Wendling, Medscape, October 16, 2019

Starting statin therapy during childhood in patients with familial hypercholesterolemia has beneficial effects on atherosclerotic progression. The cumulative incidence of cardiovascular events at age 39 years was 1% among patients with FH who began taking statins during childhood, compared with 26% among their affected parents.

DNA Tests For Psychiatric Drugs Are Controversial But Some Insurers Are Covering Them
G Dangor, NPR, October 17, 2019

Debates over efficacy: As the field of genetic testing to help diagnose and treat disease grows, medicine has embraced certain tests, such as that for the BRCA gene linked to breast cancer. But many researchers say there is not enough evidence tying genetic variants to better outcomes for most psychiatric medications.

Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
J Tie et al, JAMA Oncology, October 17, 2019

Postsurgical and post chemotherapy circulating tumor DNA analyses may identify patients at high risk of recurrence despite completing standard adjuvant treatment, presenting a unique opportunity to explore additional therapeutic approaches.


Disclaimer: Articles listed in Hot Topics of the Day are selected by Public Health Genomics Branch to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
TOP